Stay updated on Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial page.

Latest updates to the Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page shows Revision: v3.6.3, replacing the previous Revision: v3.6.2. It reflects a small backend update with no changes to the study details.SummaryDifference0.1%

- Check24 days agoChange DetectedThe page now displays Revision: v3.6.2, replacing the previous v3.6.0, signaling a minor page revision. This update appears to be a label-only change and does not modify the study content or results.SummaryDifference0.1%

- Check38 days agoChange DetectedThe page now indicates recruitment is closed for participants, and new help/navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study), along with a formatting adjustment from 'Intervention / Treatment' to 'Intervention/Treatment' and a new revision version (v3.6.0).SummaryDifference0.4%

- Check45 days agoChange DetectedThe page’s revision label was updated from v3.5.4 to v3.5.5, indicating a new internal revision was applied. This update does not modify visible study information.SummaryDifference0.1%

- Check66 days agoChange DetectedAdded a new page revision label 'Revision: v3.5.4' and removed the previous 'Revision: v3.5.3'. This indicates a minor update to the page's versioning metadata without altering the study content or available information.SummaryDifference0.1%

- Check81 days agoChange DetectedThe page’s revision label was updated from v3.5.2 to v3.5.3, signaling a minor platform/software update to the study page rather than a change to study content or results. No study data, eligibility criteria, or outcomes are altered by this update.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial page.